These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20018895)

  • 1. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.
    Wu X; Ge H; Lemon B; Vonderfecht S; Weiszmann J; Hecht R; Gupte J; Hager T; Wang Z; Lindberg R; Li Y
    J Biol Chem; 2010 Feb; 285(8):5165-70. PubMed ID: 20018895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
    Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
    Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
    PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
    PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
    Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
    FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
    Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
    J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
    Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M
    J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.
    Huang X; Yu C; Jin C; Yang C; Xie R; Cao D; Wang F; McKeehan WL
    Mol Carcinog; 2006 Dec; 45(12):934-42. PubMed ID: 16929488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fundamentals of FGF19 & FGF21 action in vitro and in vivo.
    Adams AC; Coskun T; Rovira AR; Schneider MA; Raches DW; Micanovic R; Bina HA; Dunbar JD; Kharitonenkov A
    PLoS One; 2012; 7(5):e38438. PubMed ID: 22675463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
    Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
    J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the Proliferative Potential of FGF21 or FGF19 in Liver-Specific FGFR4-Deficient Mice.
    Wäse K; Bartels T; Schwahn U; Kabiri M
    Toxicol Pathol; 2023 Jan; 51(1-2):27-38. PubMed ID: 37098695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
    Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
    Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
    Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
    Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.